IL153443A0 - Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates - Google Patents

Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates

Info

Publication number
IL153443A0
IL153443A0 IL15344301A IL15344301A IL153443A0 IL 153443 A0 IL153443 A0 IL 153443A0 IL 15344301 A IL15344301 A IL 15344301A IL 15344301 A IL15344301 A IL 15344301A IL 153443 A0 IL153443 A0 IL 153443A0
Authority
IL
Israel
Prior art keywords
alendronate
phosphonates
bis
composition
dosage form
Prior art date
Application number
IL15344301A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL153443A0 publication Critical patent/IL153443A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL15344301A 2000-06-23 2001-06-22 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates IL153443A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US26043801P 2001-01-09 2001-01-09
US09/770,898 US6476006B2 (en) 2000-06-23 2001-01-26 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
PCT/US2001/020130 WO2002000204A1 (fr) 2000-06-23 2001-06-22 Compositions et forme posologique pour liberation gastrique retardee d'alendronate et/ou d'autres bis-phosphonates

Publications (1)

Publication Number Publication Date
IL153443A0 true IL153443A0 (en) 2003-07-06

Family

ID=27395916

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15344301A IL153443A0 (en) 2000-06-23 2001-06-22 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates

Country Status (12)

Country Link
US (2) US6476006B2 (fr)
EP (1) EP1296657A1 (fr)
JP (1) JP2004501186A (fr)
KR (1) KR20030023879A (fr)
AU (2) AU2001268719B2 (fr)
CA (1) CA2412024A1 (fr)
CZ (1) CZ2003211A3 (fr)
EA (1) EA007247B1 (fr)
HU (1) HUP0301400A3 (fr)
IL (1) IL153443A0 (fr)
MX (1) MXPA02012792A (fr)
WO (1) WO2002000204A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) * 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
CA2454200A1 (fr) * 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Formes posologiques pour la liberation gastrique immediate d'un stimulateur de transport du calcium et la liberation gastrique retardee d'un bis-phosphonate
NZ534104A (en) * 2001-12-24 2007-03-30 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
JP2005522526A (ja) 2002-05-10 2005-07-28 エフ．ホフマン−ラ　ロシュ　アーゲー 骨粗鬆症の治療および予防用のビスホスホン酸
US20050026871A1 (en) * 2002-07-17 2005-02-03 Moshe Flashner-Barak Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
DE20321698U1 (de) 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
EP1790347B1 (fr) 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG Comprimé comprenant une dose haute d'ibandronate
US6846497B2 (en) * 2003-01-30 2005-01-25 National Starch And Chemical Investment Holding Corporation Rapidly expanding starches with altered crystalline structure
SI21403A (sl) * 2003-02-27 2004-08-31 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo
WO2004091601A1 (fr) * 2003-04-17 2004-10-28 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
RU2391093C2 (ru) 2003-04-24 2010-06-10 Джаготек Аг Таблетка замедленного высвобождения с заданной геометрией ядра
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
US6783772B1 (en) * 2003-12-12 2004-08-31 Sanjeev Khandelwal Pharmaceutical preparations containing alendronate sodium
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006050581A2 (fr) * 2004-11-10 2006-05-18 Jallal Messadek Betaine en tant qu'agent de lutte contre des maladies transmises par des arthropodes ou des moustiques
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
WO2006086856A1 (fr) 2005-02-15 2006-08-24 Messadek, Jallal Compositions therapeutiques combinees et leurs procedes d’utilisation
MX2007013486A (es) * 2005-04-27 2008-03-14 Jallal Messadek Combinaciones de insulinas.
US7765785B2 (en) * 2005-08-29 2010-08-03 Kashmerick Gerald E Combustion engine
CA2635594A1 (fr) * 2005-12-30 2007-07-12 Advancis Pharmaceutical Corporation Systeme gastrique a impulsions de liberation pour l'administration de medicaments
WO2008079440A2 (fr) 2006-07-10 2008-07-03 Medipacs, Inc. Hydrogel époxy super-élastique
MY149863A (en) 2006-08-03 2013-10-31 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
WO2008020305A2 (fr) * 2006-08-17 2008-02-21 Aurobindo Pharma Limited Formes pharmaceutiques solides des acides bisphosphoniques
EP1935411A1 (fr) * 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Excipient à libération prolongée et son utilisation
ATE471714T1 (de) * 2006-12-15 2010-07-15 Campina Nederland Holding Bv Hilfsstoff mit verzögerter freisetzung und seine verwendung
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
WO2009022358A1 (fr) * 2007-08-10 2009-02-19 Luigi Ambrosio Hydrogels de polymère superabsorbant et leur procédé de préparation
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
WO2009065193A1 (fr) * 2007-11-21 2009-05-28 Jallal Messadek Traitement de la résistance à l'aspirine par de la bétaïne et/ou de la mélasse enrichie en bétaïne
US9995295B2 (en) 2007-12-03 2018-06-12 Medipacs, Inc. Fluid metering device
US9457048B2 (en) 2008-02-05 2016-10-04 Wellosophy Corporation Absorbent ingestible agents and associated methods of manufacture and use
EP2210585A1 (fr) 2009-01-16 2010-07-28 Exelgyn Compositions pharmaceutiques SPRM et procédés de traitement les utilisant
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
JP5852569B2 (ja) 2009-07-31 2016-02-03 タール ファーマシューティカルズ，インコーポレイテッド 結晶化方法および生物学的利用能
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9238102B2 (en) 2009-09-10 2016-01-19 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
FR2952937B1 (fr) * 2009-11-20 2013-02-08 Chaire Europeenne De Chimie Now Pour Un Developpement Durable Nouvelles resines de type phenoplastes obtenues a partir de composes phenoliques et de durcisseurs macromoleculaire portant des fonctions aldehydes
US20110172639A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172609A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US20110172637A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172645A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
KR101324425B1 (ko) * 2011-07-22 2013-11-01 동아에스티 주식회사 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제
EP2847249A4 (fr) 2012-03-14 2016-12-28 Medipacs Inc Matériaux polymères intelligents contenant un excès de molécules réactives
CA2932574C (fr) * 2013-12-05 2023-03-07 Tulip Medical Ltd. Dispositifs et systemes de retention pour la liberation in-situ d'agents pharmaceutiques actifs
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2017208070A1 (fr) 2016-05-31 2017-12-07 Grünenthal GmbH Acide bisphosphonique et coformeurs avec lysine, glycine, nicotinamide pour le traitement de la polyarthrite psoriasique
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
EP3717453A4 (fr) 2017-12-01 2021-07-28 Ultragenyx Pharmaceutical Inc. Promédicaments à base de créatine, compositions et procédés d'utilisation associés
JP7202898B2 (ja) * 2018-01-11 2023-01-12 沢井製薬株式会社 フィルムコーティングされた口腔内崩壊錠
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3995058A (en) 1973-12-12 1976-11-30 Miles Laboratories, Inc. Treatment of ethanol withdrawal symptoms with levodopa
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4764380A (en) 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4758436A (en) 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4704285A (en) 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US4983398A (en) 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
JPH04346919A (ja) 1991-05-27 1992-12-02 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
US5198229A (en) 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
TW257765B (fr) 1993-08-25 1995-09-21 Merck & Co Inc
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
JP3601102B2 (ja) 1995-03-15 2004-12-15 ブラザー工業株式会社 インクジェット式印刷記録装置と印字システム
WO1996039410A1 (fr) 1995-06-06 1996-12-12 Merck & Co., Inc. Preparations d'alendronate disodique
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
EP0761209A3 (fr) 1995-09-01 1998-02-04 J.B. Chemicals & Pharmaceuticals Ltd. Formulations de la ranitidine à libération commandée
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
BR9811478A (pt) 1997-07-23 2000-08-15 Perio Prod Ltd Composições de polìmero-ácido tânico para a liberação controlada de agentes farmacêuticos particularmente na cavidade oral
ATE285226T1 (de) 1997-08-11 2005-01-15 Alza Corp Gastrische zurückhalteform zur verlängerten freisetzung eines wirkstoffs
IN186245B (fr) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Also Published As

Publication number Publication date
EA007247B1 (ru) 2006-08-25
US20020015733A1 (en) 2002-02-07
EA200300045A1 (ru) 2003-08-28
KR20030023879A (ko) 2003-03-20
AU2001268719B2 (en) 2006-04-27
US20030203878A1 (en) 2003-10-30
US6476006B2 (en) 2002-11-05
JP2004501186A (ja) 2004-01-15
CZ2003211A3 (en) 2004-03-17
WO2002000204A1 (fr) 2002-01-03
HUP0301400A2 (hu) 2003-09-29
CA2412024A1 (fr) 2002-01-03
EP1296657A1 (fr) 2003-04-02
MXPA02012792A (es) 2004-07-30
HUP0301400A3 (en) 2005-02-28
AU6871901A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
AU6871901A (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
IL159853A0 (en) Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
IL155293A0 (en) Delayed release pharmaceutical formulations
IL153497A0 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
GB0218157D0 (en) Compositions for controlled release
EP1424994A4 (fr) Preparation d'une composition pharmaceutique a liberation prolongee
AR027907A1 (es) Composicion de liberacion controlada
IL159626A (en) Crystalline forms of atorvastatin calcium and processes for their preparation
SG84623A1 (en) Controlled release compositions
AU5025300A (en) Compositions for controlled release of the hormone gnrh and its analogs
HUP0302522A3 (en) Thermoformable solid pharmaceutical composition for controlled release of ivabradine
GB0017468D0 (en) Silicone release coating compositions
EP1225971A4 (fr) Liberation regulee de substances
EG24463A (en) Modified release pharmaceutical composition
EP1501352A4 (fr) Methodes et compositions de liberation controlee de medicaments
HUP0104738A3 (en) Controlled release fertilizer compositions and processes for the preparation thereof
AU8456101A (en) A release composition and method of preparation
HUP0204417A3 (en) Oral ciprofloxacin-composition of controlled release
HUP0004033A2 (en) Controlled release fertilizer compositions and processes for the preparation thereof
EP1404301A4 (fr) Compositions pharmaceutiques a liberation controlee, stables, contenant de la pravastatine
AU2002359792A8 (en) Methods and compositions for the inhibition of viral release
EP1357898A4 (fr) Forme posologique orale a liberation regulee amelioree
PL360502A1 (en) Composition for inhibiting feeding of weevils
AU2002365136A8 (en) Compositions and methods for controlled release
HK1063739A1 (en) Thermoformable solid pharmaceutical composition for controlled release of perindopril